Disease activity in and quality of life of patients with psoriatic arthritis mutilans: the Nordic PAM Study.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
CitationDisease activity in and quality of life of patients with psoriatic arthritis mutilans: the Nordic PAM Study. 2017, 46 (6):454-460 Scand. J. Rheumatol.
ÚtdrátturTo describe the social status and health-related quality of life of patients with psoriatic arthritis mutilans (PAM) in the Nordic countries.
Patients with at least one mutilated joint confirmed by radiology were studied. Disease activity involving joints and skin, physician-assessed disease activity, and patient's education and work status were recorded. Data from the 36-item Short Form Health Survey, Health Assessment Questionnaire and Dermatology Life Quality Index questionnaire were gathered and correlated with disease duration, pain, and general well-being (visual analogue scale). The controls were 58 Swedish patients with long-standing psoriatic arthritis sine PAM.
Sixty-seven patients were included. Patients with PAM had a protracted disease history (33 ± 14 years) and disease onset at a relatively early age (30 ± 12 years). Overall inflammatory activity at inclusion was mild to moderate. The mean number of mutilated joints was 8.2 and gross deformity was found in 16% of patients. Forty per cent were treated with biological and 32% with conventional synthetic disease-modifying anti-rheumatic drugs. Forty-two per cent had retired early or were on sick leave. Impaired functional capacity with little or no ability to perform self-care or everyday tasks was reported by 21% of the patients. Patients between 45 and 60 years of age reported the most impaired quality of life in comparison to the control group.
PAM seriously affects social functioning. Whether early recognition of PAM and new forms of therapy can improve disease outcome and quality of life remains to be studied.
Lu00FDsingTo access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Files
RightsArchived with thanks to Scandinavian journal of rheumatology
- Psoriatic arthritis mutilans (PAM) in the Nordic countries: demographics and disease status. The Nordic PAM study.
- Authors: Gudbjornsson B, Ejstrup L, Gran JT, Iversen L, Lindqvist U, Paimela L, Ternowitz T, Ståhle M
- Issue date: 2013
- Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA).
- Authors: Theander E, Husmark T, Alenius GM, Larsson PT, Teleman A, Geijer M, Lindqvist UR
- Issue date: 2014 Feb
- Psoriatic Arthritis Mutilans: Characteristics and Natural Radiographic History.
- Authors: Jadon DR, Shaddick G, Tillett W, Korendowych E, Robinson G, Waldron N, Cavill C, McHugh NJ
- Issue date: 2015 Jul
- Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial.
- Authors: Gladman DD, Mease PJ, Cifaldi MA, Perdok RJ, Sasso E, Medich J
- Issue date: 2007 Feb
- Comparison of the Health Assessment Questionnaire and Arthritis Impact Measurement Scale in patients with psoriatic arthritis.
- Authors: Taccari E, Spadaro A, Rinaldi T, Riccieri V, Sensi F
- Issue date: 1998 Dec